News

Public · Published

TD Cowen maintains Twist Bioscience at Buy, lowers price target to $137 from $190

TD Cowen kept its Buy rating on Twist Bioscience but cut its price target to $137 from $190, a 27.9% decrease. The new target implies 19.9% upside from the November 12 closing price of $114.22.

Published:

Updated:

What happened

TD Cowen kept its Buy rating on Twist Bioscience but cut its price target to $137 from $190, a 27.9% decrease. The new target implies 19.9% upside from the November 12 closing price of $114.22.

Confirmed

Global impact / market context

The lower target signals that TD Cowen now sees less potential value in Twist Bioscience shares than before, while its unchanged Buy rating still indicates a favorable view. Investors may weigh that change against the stated 19.9% implied upside from the cited closing price.

Analyst inference

This is an analyst forecast, not a reported change in Twist Bioscience’s sales, costs, or cash available. The target is 19.9% above the cited close, but the reduction from $190 shows TD Cowen’s estimate has become more cautious.

Analyst inference

What to watch

  1. Watch for later changes to TD Cowen’s rating or target; the article reports only the current Buy rating and the reduction to $137. Analyst inference
  2. Compare future company results with the expectations behind the $137 target; the supplied article gives no reasons for the reduction or operating forecasts. Analyst inference
  3. Track whether the stated 19.9% implied upside changes as the share price moves, since it is calculated from the November 12 close of $114.22. Analyst inference

Evidence

  • Original source link unavailable